Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,070 shares of the biopharmaceutical company’s stock, valued at approximately $103,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Shine Investment Advisory Services Inc. purchased a new position in Pfizer during the 2nd quarter valued at approximately $102,000. D. Scott Neal Inc. grew its holdings in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Herndon Capital Management LLC purchased a new position in Pfizer during the 2nd quarter valued at approximately $120,000. Franklin Parlapiano Turner & Welch LLC purchased a new position in Pfizer during the 1st quarter valued at approximately $121,000. Finally, Private Vista LLC grew its holdings in Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 190,933 shares in the last quarter. 69.89% of the stock is currently owned by institutional investors.

In related news, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,280 shares of company stock valued at $2,118,988. 0.06% of the stock is owned by company insiders.

Shares of Pfizer Inc. (NYSE:PFE) traded up $0.24 during trading on Friday, hitting $35.74. The stock had a trading volume of 14,580,055 shares, compared to its average volume of 14,347,659. The stock has a market cap of $211,605.09, a PE ratio of 14.20, a price-to-earnings-growth ratio of 2.51 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a 12-month low of $30.90 and a 12-month high of $36.78.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the previous year, the business earned $0.61 EPS. Pfizer’s revenue was up .9% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.59 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date was Thursday, November 9th. Pfizer’s payout ratio is currently 79.01%.

Several equities analysts have weighed in on the company. Deutsche Bank set a $38.00 price target on Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, October 10th. Barclays set a $38.00 price target on Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price target on Pfizer and gave the company a “neutral” rating in a report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $38.77.

TRADEMARK VIOLATION WARNING: “Mckinley Capital Management LLC Delaware Takes Position in Pfizer Inc. (PFE)” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/12/09/mckinley-capital-management-llc-delaware-takes-position-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.